



Scott Brooks Joins RegenesiS Biomedical as Chief Operating Officer

New leadership role as the company expands market reach

Scottsdale, Arizona, January 16, 2012 -- RegenesiS Biomedical, Inc., a medical technology company that markets the Provant[®] Therapy System, announced today that Scott Brooks has joined the company in the newly created position of Chief Operating Officer. Scott is responsible for helping scale the organization's capabilities to support increased market penetration and broadened reimbursement.

Most recently Scott was President of sales, marketing and customer service at BSN Medical located in Charlotte, NC. He led a team of 190 people in the US and Canada. Prior to that, Scott was the VP of Sales and National Accounts at Kinetic Concepts Inc. (KCI), the marketer of the wound VAC. At KCI he managed a team of sales and national accounts professionals who sold advanced wound care, critical care, and bariatric care devices in the US to hospitals, nursing homes, and homecare. Scott served on the KCI management team as the company emerged into a global leader. His experience includes successful leadership positions with The Hill-Rom Company, Kimberly Clark Health Care, and Covidien.

"Scott is a mission focused, strategic, and process minded leader with experience scaling an organization," said Virginia Rybski, President and CEO of RegenesiS. "We look forward to his contributions in building upon our performance based culture."

About RegenesiS Biomedical

RegenesiS Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. RegenesiS developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

About the Provant[®] Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: RegenesiS Biomedical, Inc.
Scott Robey, Vice President Marketing
www.regenesibio.com
480-970-4970 phone

SOURCE: RegenesiS Biomedical Inc.